George Clinical’s scientific leadership is primarily focused on developing new strategies for the prevention of heart diseases by targeting their primary risk factors such as high blood pressure and cholesterol, through drug and device interventions.
George Clinical has the breadth of expertise and clinical networks to make what is traditionally one of the most complex and time consuming therapeutic areas to conduct clinical trials, one of the most streamlined.
Heart disease is the leading cause of death in the world. It accounts for more than 17 million deaths a year and that figure is rising. George Clinical’s scientific leadership is primarily focused on developing new strategies for the prevention of heart diseases by targeting their primary risk factors such as high blood pressure and cholesterol, through drug and device interventions.
The depth of George Clinical’s therapeutic expertise places us as global experts in designing and implementing studies measuring cardiovascular co-morbidities and outcomes to the highest scientific standard.
George Clinical’s scientific leadership have an impressive track record providing evidence to effect real change in practice and policy so that our research translates into clinical practice and government policy.
Our clinical trial services in cardiovascular health include:
George Clinical’s expertise and capacity to engage with significant investigator networks, place us as one of the leading cardiovascular contract research organizations operating in this therapeutic area.
Dr. Kosiborod’s research has a strong focus on the intersection of diabetes and cardiovascular disease. He is Vice President of Research at Saint Luke’s Health System; Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute; and Professor of Medicine at the University of Missouri-Kansas City. He is an internationally recognized expert in diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, as well as quality of care and outcomes. He received training in clinical research, epidemiology and health policy through the Robert Wood Johnson Clinical Scholars Program, as well as clinical training in cardiovascular medicine at Yale University School of Medicine.
As a practicing clinician and researcher, Dr. Kosiborod seeks to establish a practical system of implementing adoption of new treatments that have been proven to be life saving into practice in a more timely manner. He continues to be involved in the leadership of numerous clinical trials and multi-center registries, and serve as the Principal Investigator of investigator-initiated, multi-center trials in diabetes and cardiovascular disease, most recently of SGLT2 inhibition.
Research interests include the environmental determinants of chronic disease and the potential for changes in the food supply to deliver large, cost-effective and equitable health gains. Founding member and Executive Director, The George Institute for Global Health; Professor of Medicine, UNSW Sydney; and Professor of Clinical Epidemiology at Imperial College London. Expertise in the management of high blood pressure and diabetes and has played lead roles in multiple large-scale clinical trials.
Professor Rodgers’ principal focus is on cardiovascular disease prevention, innovation and public-private partnerships, and in scaleable interventions to address major health risks. He is Professor of Global Health at The George Institute for Global Health and Chair of Clinical Epidemiology, Imperial College London. He was the principal author of the 2002 World Health Report, the main annual publication for WHO.
Since 2003 Professor Rodgers has led a public-private partnership developing an affordable four-in-one cardiovascular combination pill (‘polypill’), with a clinical trial program in economically developed and developing countries, funded by the Wellcome Trust, European Union and others. His current work aims to foster similar developments designed to be ‘fit for purpose’ in low income settings.
Dr. Sundström’s research focuses on causes and consequences of hypertension. He is Professor of Epidemiology at Uppsala University; Conjoint Professor at The George Institute for Global Health, University of New South Wales; and a clinical specialist in the internal medicine and cardiology at Department of Cardiology, Uppsala University Hospital. He also heads the university’s Clinical Epidemiology research group.
Dr. Sundström is interested in using big data to create value for patients and populations and developing methods for risk estimation, treatment decisions and evaluation of treatment effects, risks and costs. In addition to creating data sources such as clinical trials and cohorts, he develops methods for emerging ones such as electronic health records and digital patient-generated data. He has made important contributions to the understanding of cardiovascular disease and its risk factors, with a focus on high blood pressure, and his work is cited in several international cardiovascular prevention and hypertension guidelines. At the George Institute for Global Health at Sydney University, he initiated a series of studies in the Blood Pressure Lowering Treatment Trialists’ Collaboration investigating optimal targeting of blood pressure-lowering treatment. He is currently contributing with unique research of the potential for “precision medicine”in cardiovascular disease.
Professor Chalmers’ research interests include large scale clinical trials and epidemiological studies related to hypertension, coronary heart disease and stroke, and diabetes and renal disease. He is Senior Director, Professorial Unit, The George Institute for Global Health and Professor of Medicine, UNSW Sydney, as well as Emeritus Professor of Medicine at Flinders University and at the University of Sydney.
At the George Institute, he serves as Principal Investigator on research grants and chair of steering committees for major studies.
Professor Chalmers’ studies on the treatment of high blood pressure for the prevention of heart attack and stroke have changed the way patients are treated throughout the world. They helped elucidate the brain mechanisms and neurotransmitters responsible for blood pressure control, and also demonstrated the benefits to stroke and Type II diabetes patients of lowering their blood pressure – whether it is considered clinically “high” or not. His contribution to medical science has been recognized through many awards, Honorary Doctoral degrees and extensive appointments on national and international boards and advisory committees. He was appointed a Companion in the Order of Australia (AC) in 1991 and an Officer in the National Order of Merit of France in 2010.
